UNSPSC 51382601: Carbasalate calcium

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula 2C9H7O4.CH4N2O.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N667F17JP1, chemically known as salicylic acid acetate calcium salt, compound with urea (1:1) complex but generally known as carbasalate calcium, which bears US NIH Compound Identifier 21975. European Medicines Agency schedules Carbasalate calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06117MIG.

World Health Organization schedules carbasalate calcium in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule carbasalate calcium under HS 29242995 and SITC 51479. SMILES: CC(=O)OC1=CC=CC=C1C(=O)[O-].CC(=O)OC1=CC=CC=C1C(=O)[O-].C(=O)(N)N.[Ca+2].

UNSPSC 51382601 Carbasalate calcium is a Commodity code that nominally designates a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code does not align with the ingredient itself. Instead, the opportunities posted against this code span naloxone procurement, direct-to-manufacturer pharmacy programs, and multi-source generic pharmaceutical supply agreements — products and services substantially broader than carbasalate calcium. State and local governments are using this code to solicit pharmaceutical supply, emergency medical countermeasures, and pharmacy benefit management services across health departments, state health agencies, and cooperative purchasing alliances. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing organizations that aggregate demand for member state and local governments.

Recent activity centers on Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 for naloxone and drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries), with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities, including Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The code shows material mismatch between its nominal scope and the pharmaceutical supply, emergency response, and pharmacy program management work actually being solicited under it.